ALPS Advisors’s Iovance Biotherapeutics IOVA Stock Holding History

ALPS Advisors’s Portfolio IOVA Stock Details IOVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-86,118	Closed	-$825K	–	1059
2022 Q3	$825K	Sell	86,118 -7,118	-8%	-$82.1K	0.01%	506
2022 Q2	$1.03M	Sell	93,236 -68,292	-42%	-$895K	0.01%	469
2022 Q1	$2.69M	Sell	161,528 -17,891	-10%	-$277K	0.03%	174
2021 Q4	$3.42M	Sell	179,419 -10,600	-6%	-$233K	0.04%	177
2021 Q3	$4.69M	Sell	190,019 -10,411	-5%	-$245K	0.05%	178
2021 Q2	$5.21M	Buy	+200,430	New	+$5.21M	0.05%	173

Other funds holding IOVA

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

MFM

MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

ALPS Advisors's IOVA Position: Q4 2022 in Review

ALPS Advisors sold out of Iovance Biotherapeutics (IOVA) in Q4 2022, closing a stake of 86,118 shares — an estimated $825K sold.

ALPS Advisors first reported a position in IOVA in Q2 2021 and held it in 6 quarters. The position peaked at $5.21M in Q2 2021. 218 funds tracked by Wall St. Rank hold IOVA as of Q4 2022.

ALPS Advisors reported no remaining Iovance Biotherapeutics position as of Q4 2022 after selling out during the quarter.
ALPS Advisors sold 86,118 Iovance Biotherapeutics shares in Q4 2022, an estimated $825K.
ALPS Advisors first reported a position in Iovance Biotherapeutics in Q2 2021 and held it in 6 quarters.
ALPS Advisors's Iovance Biotherapeutics position peaked at $5.21M in Q2 2021.
218 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q4 2022.

Based on ALPS Advisors's 13F filing for Q4 2022, filed 14 Feb 2023.